A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma

Anti-angiogenic therapy, targeting vascular endothelial growth factor (VEGF)-A/VEGF receptors (VEGFRs), is beneficial for tumor growth prevention in a malignant glioma. A simultaneous blockade using both bevacizumab (Bev), which targets circulating VEGF-A, and a multi-kinase inhibitor on VEGFRs was...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Vaccines (Basel)
Huvudupphovsmän: Tamura, Ryota, Morimoto, Yukina, Sato, Mizuto, Hikichi, Tetsuro, Yoshida, Kazunari, Toda, Masahiro
Materialtyp: Artigo
Språk:Inglês
Publicerad: MDPI 2020
Ämnen:
Communication
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7564945/
https://ncbi.nlm.nih.gov/pubmed/32887369
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/vaccines8030498
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk